Histo- und Molekularpathologie bei gastroenteropankreatischen neuroendokrinen Neoplasien

Die pathologische Differenzierung der neuroendokrinen Neoplasien (NEN) leistet einen wichtigen Beitrag in der Primärdiagnostik und kann in der metastasierten Situation bei unklarem Primarius den entscheidenden Hinweis auf den Primärtumor liefern. Histologische und molekularpathologische Merkmale der NEN können in das klinisch-therapeutische Management einbezogen werden und werden im Folgenden bei NEN des gastroenteropankreatischen Systems vorgestellt.

Abstract

Neuroendocrine neoplasms are classified according to the WHO classification based on morphological criteria into neuroendocrine tumors, neuroendocrine carcinomas, and mixed neuroendocrine-non-neuroendocrine neoplasms. Neuroendocrine tumors are well differentiated neoplasms and show characteristic site-specific histological and molecular features, which is important for their clinical management. In cases dealing with metastasis, pathology often can help to identify the primary tumors using a small immunohistochemical marker panel. Neuroendocrine carcinomas are poorly differentiated neoplasms. They are subdivided into neuroendocrine carcinomas of small cell and large cell type. The molecular profile of neuroendocrine carcinomas and mixed neuroendocrine-non-neuroendocrine neoplasms shows a close relationship to conventional adenocarcinomas with site-specific features. Molecular analysis of neuroendocrine carcinomas and neuroendocrine-non-neuroendocrine neoplasms are not yet fully integrated in daily diagnostics and are mainly performed in the context of precision oncology.

Kernaussagen

• Die WHO-Klassifikation teilt die neuroendokrinen Neoplasien anhand morphologischer Kriterien in neuroendokrine Tumoren, neuroendokrine Karzinome und gemischte neuroendokrine, nicht neuroendokrine Neoplasien ein.

• Neuroendokrine Tumoren sind gut differenziert und zeigen lokalisationsspezifisch charakteristische histologische und molekulare Merkmale, die essenziell für das klinisch-therapeutische Management sind.

• In der Diagnostik von Metastasen bei unklarem Primarius kann die pathologisch-anatomische Diagnostik mit einem kleinen immunhistochemischen Markerpanel den entscheidenden Hinweis für die Lokalisation des Primarius liefern.

• Neuroendokrine Karzinome sind schlecht differenziert und werden weiter in kleinzellige und großzellige Typen unterteilt.

• Das molekulare Profil der neuroendokrinen Karzinome und der gemischten neuroendokrinen, nicht neuroendokrinen Neoplasien zeigt organspezifische Merkmale und orientiert sich an dem genetischen Profil der konventionellen Adenokarzinome.

• Die molekularen Analysen sind bei den neuroendokrinen Karzinomen und den gemischten neuroendokrinen, nicht neuroendokrinen Neoplasien noch nicht vollständig in den diagnostischen Alltag integriert und werden zurzeit vor allem im Rahmen von molekularen Tumorboards durchgeführt.

Schlüsselwörter

neuroendokriner Tumor - neuroendokriner Tumor - Neoplasie - Ki67 - Molekularpathologie

Keywords

neuroendocrine tumor - neuroendocrine carcinoma - neoplasm - Ki67 - molecular pathology

Publikationsverlauf

Artikel online veröffentlicht:
16. Juli 2024

• Literatur

• 1 WHO Classification of Tumours Editorial Board. Digestive System Tumours. 5. Aufl.. Lyon: IARC; 2019
• 2 Lloyd RV, Osamura RY, Klöppel G. et al. WHO Classification of Tumours of Endocrine Organs. Lyon: IARC Press; 2017
• 3 WHO Classification of Tumours Editorial Board. Endocrine and neuroendocrine tumours. Lyon: IARC; 2022
• 4 Kloppel G. Neoplasms of the disseminated neuroendocrine cell system of the gastrointestinal tract. Pathologe 2015; 36 (03) 237-245
• 5 Klöppel G. Neuroendokrine Neoplasien. In: Stolte M, Rüschoff J, Klöppel G. Pathologie – Verdauungstrakt und Peritoneum. Berlin Heidelberg: Springer; 2013
• 6 Kloppel G, Dege K, Remmele W. et al. Siegfried Oberndorfer: a tribute to his work and life between Munich, Kiel, Geneva, and Istanbul. Virchows Arch 2007; 451 (Suppl. 01) S3-S7
• 7 Soga J, Tazawa K. Pathologic analysis of carcinoids. Histologic reevaluation of 62 cases. Cancer 1971; 28 (04) 990-998
• 8 Konukiewitz B, von Hornstein M, Jesinghaus M. et al. Pancreatic neuroendocrine tumors with somatostatin expression and paraganglioma-like features. Hum Pathol 2020; 102: 79-87
• 9 Anlauf M, Perren A, Kloppel G. Endocrine precursor lesions and microadenomas of the duodenum and pancreas with and without MEN1: criteria, molecular concepts and clinical significance. Pathobiology 2007; 74 (05) 279-284
• 10 Anlauf M, Garbrecht N, Henopp T. et al. Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features. World J Gastroenterol 2006; 12 (34) 5440-5446
• 11 Corbo V, Dalai I, Scardoni M. et al. MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. Endocr Relat Cancer 2010; 17 (03) 771-783
• 12 Marini F, Falchetti A, Luzi E. et al. Multiple Endocrine Neoplasia Type 1 (MEN1) Syndrome. In: Riegert-Johnson DL, Boardman LA, Hefferon T, Roberts M. Cancer Syndromes. Bethesda (MD): National Center for Biotechnology Information; 2009
• 13 Konukiewitz B, Enosawa T, Kloppel G. Glucagon expression in cystic pancreatic neuroendocrine neoplasms: an immunohistochemical analysis. Virchows Arch 2011; 458 (01) 47-53
• 14 Konukiewitz B, Jesinghaus M, Kasajima A. et al. Neuroendocrine neoplasms of the pancreas: diagnosis and pitfalls. Virchows Arch 2022; 480 (02) 247-257
• 15 Konukiewitz B, Schlitter AM, Jesinghaus M. et al. Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20. Mod Pathol 2017; 30 (04) 587-598
• 16 Grass A, Kasajima A, Foersch S. et al. PITX2 as a Sensitive and Specific Marker of Midgut Neuroendocrine Tumors: Results from a Cohort of 1157 Primary Neuroendocrine Neoplasms. Mod Pathol 2024; 100442
• 17 Nesti C, Brautigam K, Benavent M. et al. Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study. Lancet Oncol 2023; 24 (02) 187-194
• 18 McCall CM, Shi C, Klein AP. et al. Serotonin expression in pancreatic neuroendocrine tumors correlates with a trabecular histologic pattern and large duct involvement. Hum Pathol 2012; 43 (08) 1169-1176
• 19 Scarpa A, Chang DK, Nones K. et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature 2017; 543 (7643) 65-71
• 20 Hackeng WM, Brosens LA, Poruk KE. et al. Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis. Hum Pathol 2016; 56: 93-100
• 21 Perren A, Anlauf M, Henopp T. et al. Multiple endocrine neoplasia type 1 (MEN1): loss of one MEN1 allele in tumors and monohormonal endocrine cell clusters but not in islet hyperplasia of the pancreas. J Clin Endocrinol Metab 2007; 92 (03) 1118-1128
• 22 Konukiewitz B, Jesinghaus M, Steiger K. et al. Pancreatic neuroendocrine carcinomas reveal a closer relationship to ductal adenocarcinomas than to neuroendocrine tumors G3. Hum Pathol 2018; 77: 70-79
• 23 Nieser M, Henopp T, Brix J. et al. Loss of Chromosome 18 in Neuroendocrine Tumors of the Small Intestine: The Enigma Remains. Neuroendocrinology 2017; 104 (03) 302-312
• 24 Kloppel G, La Rosa S. Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms. Virchows Arch 2018; 472 (03) 341-349
• 25 Di Domenico A, Pipinikas CP, Maire RS. et al. Epigenetic landscape of pancreatic neuroendocrine tumours reveals distinct cells of origin and means of tumour progression. Commun Biol 2020; 3 (01) 740
• 26 Marinoni I, Kurrer AS, Vassella E. et al. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology 2014; 146 (02) 453-460
• 27 Kasajima A, Konukiewitz B. et al. An analysis of 130 neuroendocrine tumors G3 regarding prevalence, origin, metastasis, and diagnostic features. Virchows Arch 2022; 480 (02) 359-368
• 28 Brautigam K, Chouchane A, Konukiewitz B. et al. Practical application of immunohistochemistry in pancreatic neuroendocrine neoplasms : Tips and pitfalls. Pathologie 2024; 45 (01) 35-41
• 29 Yachida S, Vakiani E, White CM. et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol 2012; 36 (02) 173-184
• 30 Jesinghaus M, Konukiewitz B, Keller G. et al. Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas. Mod Pathol 2017; 30 (04) 610-619
• 31 Griger J, Widholz SA, Jesinghaus M. et al. An integrated cellular and molecular model of gastric neuroendocrine cancer evolution highlights therapeutic targets. Cancer cell 2023; 41 (07) 1327-1344
• 32 Jesinghaus M, Schmitt M, Lang C. et al. Morphology Matters: A Critical Reappraisal of the Clinical Relevance of Morphologic Criteria From the 2019 WHO Classification in a Large Colorectal Cancer Cohort Comprising 1004 Cases. Am J Surg Pathol 2021; 45 (07) 969-978
• 33 Klöppel G, Clemens A. The biological relevance of gastric neuroendocrine tumors. The Yale journal of biology and medicine 1996; 69 (01) 69-74